Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease | Completed
Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease
Health Conditions
  • Dyspnea
  • Lung Cancer
  • Metastatic Cancer
Completed
Recruitment Status
NCT01138358
Primary Trial ID Number
Summary
RATIONALE: Gathering information about experiences of episodic breathlessness in patients with advanced disease may help doctors learn more about the disease. PURPOSE: This clinical trial is studying experiences of episodic breathlessness in patients with lung cancer or other advanced disease.
Primary Outcome Measures
  • Experiences of episodic breathlessness; null; Impact of episodic breathlessness on daily living; null; Individual coping strategies to reduce burden of episodic breathlessness; null
Secondary Outcome Measures
    Sorry, this information is not available
Research Question
  • RATIONALE: Gathering information about experiences of episodic breathlessness in patients with advanced disease may help doctors learn more about the disease. PURPOSE: This clinical trial is studying experiences of episodic breathlessness in patients with lung cancer or other advanced disease.
Design Type
Sorry, this information is not available
Ethics Approval
Sorry, this information is not available
Publications
Sorry, this information is not available
Countries of Recruitment
United Kingdom
Participant Sex
Both
Participant Age Range
18 Years to N/A
Participant Type
Sorry, this information is not available
Trial Sample Size
50
Participant Inclusion Criteria
  • DISEASE CHARACTERISTICS:
  • - Diagnosis of advanced disease as defined by the following criteria:
  • - Lung cancer
  • - Primary lung cancer at all stages (small cell lung cancer [SCLC] and
  • non-small cell lung cancer [NSCLC])
  • - Cancer at any site with secondary tumor of the lung (lung metastasis)
  • - Chronic obstructive pulmonary disease (COPD)
  • - Stage III or IV of the Global Initiative for Obstructive Lung Disease
  • (GOLD) classification, which includes the airflow limitation measured by
  • spirometry FEV1 < 50%, FEV1/FVC < 0.7, and symptoms such as more severe
  • breathlessness, reduced exercise capacity, and repeated exacerbations
  • - Chronic heart failure (CHF)
  • - NYHA class II-IV heart disease, which includes symptoms such as dyspnea or
  • palpitation and an increasing limitation of exercise capacity or discomfort
  • at rest
  • - Motor neuron disease (MND)
  • - All patients suffering from breathlessness
  • - Suffering from episodic breathlessness as defined above at any level of severity
  • PATIENT CHARACTERISTICS:
  • - Able to give informed consent
  • - Able to be interviewed
  • - No cognitive impairment (clinically judged by the principal investigator)
  • - No limited comprehension of the English language
  • PRIOR CONCURRENT THERAPY:
  • - Concurrent disease-oriented therapies (e.g., chemotherapy, radiotherapy, or surgery)
  • allowed
Participant Exclusion Criteria
  • DISEASE CHARACTERISTICS:
  • - Diagnosis of advanced disease as defined by the following criteria:
  • - Lung cancer
  • - Primary lung cancer at all stages (small cell lung cancer [SCLC] and
  • non-small cell lung cancer [NSCLC])
  • - Cancer at any site with secondary tumor of the lung (lung metastasis)
  • - Chronic obstructive pulmonary disease (COPD)
  • - Stage III or IV of the Global Initiative for Obstructive Lung Disease
  • (GOLD) classification, which includes the airflow limitation measured by
  • spirometry FEV1 < 50%, FEV1/FVC < 0.7, and symptoms such as more severe
  • breathlessness, reduced exercise capacity, and repeated exacerbations
  • - Chronic heart failure (CHF)
  • - NYHA class II-IV heart disease, which includes symptoms such as dyspnea or
  • palpitation and an increasing limitation of exercise capacity or discomfort
  • at rest
  • - Motor neuron disease (MND)
  • - All patients suffering from breathlessness
  • - Suffering from episodic breathlessness as defined above at any level of severity
  • PATIENT CHARACTERISTICS:
  • - Able to give informed consent
  • - Able to be interviewed
  • - No cognitive impairment (clinically judged by the principal investigator)
  • - No limited comprehension of the English language
  • PRIOR CONCURRENT THERAPY:
  • - Concurrent disease-oriented therapies (e.g., chemotherapy, radiotherapy, or surgery)
  • allowed
Interventions
Other; medical chart review; null; []; Other; study of socioeconomic and demographic variables; null; []; Other; survey administration; null; []; Procedure; quality-of-life assessment; null; []
Design Details
Sorry, this information is not available
Study Design
N/A
Results Reporting
Sorry, this information is not available
Acronym
Sorry, this information is not available
Scientific Title
Experiences of Episodic Breathlessness (EB) in Patients With Advanced Disease
Secondary Trial Identifying Number
UKM-KCH-EB-V4; EU-21039
Website
http://cancer.gov/clinicaltrials/UKM-KCH-EB-V4
Study Funded By
King's College Hospital NHS Trust
Funder Type
Sorry, this information is not available
Study Sponsored By
King's College Hospital NHS Trust
Study Also Sponsored By
Sorry, this information is not available
Primary Sponsor Type
Sorry, this information is not available
Secondary Sponsor Type
Sorry, this information is not available
Key Dates

Date of First Enrollment
Date Not Available
Recruitment End Date
Date Not Available
Trial End Date
Date Not Available
Date added to Registry

04 Jun 2010

Last Updated

23 Aug 2013

Date Record Refreshed on UKCTG

31 Jul 2015